News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Maite Gorostegui: Our paper about Management of High-Risk Neuroblastoma in the Era of Anti-GD2 Immunotherapy
Maite Gorostegui/LinkedIn
May 5, 2024, 14:01

Maite Gorostegui: Our paper about Management of High-Risk Neuroblastoma in the Era of Anti-GD2 Immunotherapy

Maite Gorostegui, Pediatric Oncologist at Pediatric Cancer Center Barcelona, shared a post on LinkedIn:

“We just published our paper about Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy.
These heterogeneous group of patients with locoregional disease are at risk to be over/undertreated. To determine biology is fundamental for their prognosis. We report on patients with high risk biology and the positive impact of immunotherapy on these selected group of patients.

Hospital Sant Joan de Déu Barcelona
Jaume Mora, Cinzia Lavarino, Noelia Salvador, Lucas Krauel,Alicia Castañeda, Moira Garraus Oneca Cristina L., Juan Pablo Muñoz, Sara Perez-Jaume, Margarida Simao-Rafael, Salvador Mañe.”

Maite Gorostegui

Read further.
Source: Maite Gorostegui/LinkedIn

Alicia Castañeda Anti-GD2 Immunotherapy cancer Cinzia Lavarino High-Risk Neuroblastoma immunotherapy Jaume Mora Juan Pablo Muñoz Lucas Krauel Maite Gorostegui Margarida Simao-Rafael Moira Garraus Oneca Cristina L. Noelia Salvador OncoDaily Oncology Pediatric Cancer Center Barcelona Salvador Mañe Sara Perez-Jaume
Special Coverage
Insight
Dec 22, 2024, 00:21
Eric J. Small: ASCO/Conquer Cancer Foundation Felix Feng Prostate Cancer YIA is now fully endowed
Blog
Dec 21, 2024, 22:40
50 Years of History, a Future to Write Together - AIEOP
Science
Dec 21, 2024, 22:37
Breaking Down the Impact of Ionizing Radiation on Cancer
Blog
Dec 21, 2024, 22:35
Santiago Viteri: Latest findings from the BR.31 trial presented at the 2024 ESMO Congress
Blog
Dec 21, 2024, 22:33
ABIM will develop two new assessment options focusing on breast cancer and hematologic neoplasms
Blog
Dec 21, 2024, 22:28
Adekemi Oyewusi: EDUCARE - Supporting the medical treatment and education of those impacted by childhood cancer
Blog
Dec 21, 2024, 22:26
Anas Younes: Transforming outcomes for people living with Blood Cancer
Blog
Dec 21, 2024, 19:42
Ruben Mesa: Over 200 research staff of Atrium Health Wake Forest Baptist trained on Just Ask Increasing Diversity in Cancer Clinical Trials
Blog
Dec 21, 2024, 19:39
Kyaw Thein: Investigational Treatments for Thyroid and Head and Neck Cancers
Blog
Dec 21, 2024, 19:25
Hesham ElGhazaly: From an academic institution into a globally recognized hub for healthcare, research and innovation
Blog
Dec 21, 2024, 19:21
Douglas Flora: The 19 Words I’m Learning to Embrace as a Leader in 2025
Blog
Dec 21, 2024, 19:19
Registration and abstract submission open for the PTCOG63 - SIOP Europe